The future of plague vaccines: Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate

Jason A. Rosenzweig, Ashok K. Chopra

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Yersinia pestis (YP) is the Gram-negative etiological agent of plague against which no commercial vaccine exists to prophylactically prevent a potential outbreak due to natural or bio-warfare/terrorism-mediated causes. The US FDA only recently approved levofloxacin to combat this deadly pathogen. In the article under review, an attenuated, recombinant Salmonella typhimurium ΔphoPQ mutant strain producing YP antigens F1, LcrV and F1-V (fusion protein) from either low-copy pBR or high-copy pUC vectors (maintained by plasmid addiction rather than antibiotic selection pressure) were evaluated for their ability to induce a humoral immune response in both mice and rabbits. This study highlights the need for developing a well-tolerated YP vaccine that, through the oral route, can be readily administered and elicit both mucosal and systemic anti-plague humoral immunity.

Original languageEnglish (US)
Pages (from-to)659-661
Number of pages3
JournalExpert review of vaccines
Volume11
Issue number6
DOIs
StatePublished - Jun 1 2012

Keywords

  • F1
  • LcrV antigen
  • Salmonella typhimurium-attenuated ΔphoP/Q mutant
  • Yersinia pestis vaccine
  • balanced lethal plasmids

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'The future of plague vaccines: Hopes raised by a surrogate, live-attenuated recombinant vaccine candidate'. Together they form a unique fingerprint.

  • Cite this